Charles Schwab’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

Charles Schwab’s Portfolio FMTX Stock Details FMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-274,027	Closed	-$5.47M	–	3613
2022 Q3	$5.47M	Buy	274,027 +35,146	+15%	+$464K	﹤0.01%	2168
2022 Q2	$1.65M	Buy	238,881 +18,982	+9%	+$133K	﹤0.01%	2623
2022 Q1	$2.05M	Sell	219,899 -8,494	-4%	-$90.4K	﹤0.01%	2642
2021 Q4	$3.25M	Buy	228,393 +2,832	+1%	+$49K	﹤0.01%	2553
2021 Q3	$5.23M	Buy	225,561 +60,228	+36%	+$1.42M	﹤0.01%	2354
2021 Q2	$4.12M	Buy	165,333 +7,831	+5%	+$210K	﹤0.01%	2440
2021 Q1	$4.41M	Buy	157,502 +31,026	+25%	+$1.12M	﹤0.01%	2361
2020 Q4	$4.42M	Buy	126,476 +27,609	+28%	+$1.2M	﹤0.01%	2281
2020 Q3	$4.93M	Buy	+98,867	New	+$4M	﹤0.01%	2062

Charles Schwab's FMTX Position: Q4 2022 in Review

Charles Schwab sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 274,027 shares — an estimated $5.47M sold.

Charles Schwab first reported a position in FMTX in Q3 2020 and held it in 9 quarters. The position peaked at $5.47M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

Charles Schwab reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Charles Schwab sold 274,027 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $5.47M.
Charles Schwab first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
Charles Schwab's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $5.47M in Q3 2022.
0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.